Pre-order Enquiry
Request Free Sample
Catheter-Related Bloodstream Infection (CRBSI) - Epidemiology Forecast to 2028
SKU ID : DEL-15560610 | Publishing Date : 01-Apr-2020 | No. of pages : 156
Request Sample
Request Customization
Check DiscountsDetailed TOC of Catheter-Related Bloodstream Infection (CRBSI) - Epidemiology Forecast to 2028
1. Key Insights2. Catheter-Related Blood Stream Infection (CRBSI): Epidemiology Overview at a Glance
2.1. Total Incident cases of CRBSI in 2017 and 2028
3. Catheter-Related Bloodstream Infection (CRBSI): Disease Background and Overview
3.1. Introduction
3.2. Difference between CLABSI and CRBSI
3.3. Causes of Catheter-Related Bloodstream Infection (CRBSI)
3.3.1. Micro-organisms
3.3.2. Intravascular Devices
3.4. Risk Factor Associated with Catheter-Related Bloodstream Infection (CRBSI)
3.5. Pathogenesis of Catheter-Related Bloodstream Infection (CRBSI)
3.6. Diagnosis of Catheter-Related Bloodstream Infection (CRBSI)
3.7. Diagnosis Guidelines Catheter-Related Bloodstream Infection (CRBSI)
3.7.1. Infectious Diseases Society of America (IDSA) Guidelines for CRBSI
3.7.2. Spanish Society of Infectious Diseases and Clinical Microbiology and (SEIMC) and the Spanish Society of Intensive and Critical Care Medicine and Coronary Units (SEMICYUC)
3.7.3. British Intestinal Failure Alliance (BIFA)
3.7.4. European Renal Best Practice (ERBP) Recommendations for Diagnosis of CRBSIs
4. Epidemiology and Patient Population
4.1.1. Key Findings
4.1.2. Total Incident Population of CRBSI in the Global Market
4.1.3. Total Diagnosed Incident Population of CRBSI in the Global Market
4.1.4. Some KOL Insights
5. United States Epidemiology
5.1. Assumptions and Rationale
5.2. Total Incident Population of CRBSI in the United States
5.3. Total Diagnosed Incident Population of CRBSI in the United States
5.4. Diagnosed Incidence of CRBSI by Causative Pathogens in the United States
6. EU5 Epidemiology
6.1. Germany Epidemiology
6.1.1. Assumptions and Rationale
6.1.2. Total Incident Population of CRBSI in Germany
6.1.3. Total Diagnosed Incident Population of CRBSI in Germany
6.1.4. Diagnosed Incidence of CRBSI by Causative Pathogens in Germany
6.2. France Epidemiology
6.2.1. Assumptions and rationale
6.2.2. Total Incident Population of CRBSI in France
6.2.3. Total Diagnosed Incident Population of CRBSI in France
6.2.4. Diagnosed Incidence of CRBSI by Causative Pathogens in France
6.3. Italy Epidemiology
6.3.1. Assumptions and Rationale
6.3.2. Total Incident Population of CRBSI in Italy
6.3.3. Total Diagnosed Incident Population of CRBSI in Italy
6.3.4. Diagnosed Incidence of CRBSI by Causative Pathogens in Italy
6.4. Spain Epidemiology
6.4.1. Assumptions and Rationale
6.4.2. Total Incident Population of CRBSI in Spain
6.4.3. Total Diagnosed Incident Population of CRBSI in Spain
6.4.4. Diagnosed Incidence of CRBSI by Causative Pathogens in Spain
6.5. United Kingdom Epidemiology
6.5.1. Assumptions and Rationale
6.5.2. Total Incident Population of CRBSI in the United Kingdom
6.5.3. Total Diagnosed Incident Population of CRBSI in the United Kingdom
6.5.4. Diagnosed Incidence of CRBSI by Causative Pathogens in the United Kingdom
7. APAC Epidemiology
7.1. Japan Epidemiology
7.1.1. Assumptions and Rationale
7.1.2. Total Incident Population of CRBSI in Japan
7.1.3. Total Diagnosed Incident Population of CRBSI in Japan
7.1.4. Diagnosed Incidence of CRBSI by Causative Pathogens in Japan
7.2. China Epidemiology
7.2.1. Assumptions and Rationale
7.2.2. Total Incident Population of CRBSI in China
7.2.3. Total Diagnosed Incident Population of CRBSI in China
7.2.4. Diagnosed Incidence of CRBSI by Causative Pathogens in China
7.3. India Epidemiology
7.3.1. Assumptions and Rationale
7.3.2. Total Incident Population of CRBSI in India
7.3.3. Total Diagnosed Incident Population of CRBSI in India
7.3.4. Diagnosed Incidence of CRBSI by Causative Pathogens in India
7.4. Taiwan Epidemiology
7.4.1. Assumptions and Rationale
7.4.2. Total Incident Population of CRBSI in Taiwan
7.4.3. Total Diagnosed Incident Population of CRBSI in Taiwan
7.4.4. Diagnosed Incidence of CRBSI by Causative Pathogens in Taiwan
7.5. South Korea Epidemiology
7.5.1. Assumptions and Rationale
7.5.2. Total Incident Population of CRBSI in South Korea
7.5.3. Total Diagnosed Incident Population of CRBSI in South Korea
7.5.4. Diagnosed Incidence of CRBSI by Causative Pathogens in South Korea
7.6. Australia Epidemiology
7.6.1. Assumptions and Rationale
7.6.2. Total Incident Population of CRBSI in Australia
7.6.3. Total Diagnosed Incident Population of CRBSI in Australia
7.6.4. Diagnosed Incidence of CRBSI by Causative Pathogens in Australia
8. LATAM Epidemiology
8.1. Argentina Epidemiology
8.1.1. Assumptions and Rationale
8.1.2. Total Incident Population of CRBSI in Argentina
8.1.3. Total Diagnosed Incident Population of CRBSI in Argentina
8.1.4. Diagnosed Incidence of CRBSI by Causative Pathogens in Argentina
8.2. Brazil Epidemiology
8.2.1. Assumptions and Rationale
8.2.2. Total Incident Population of CRBSI in Brazil
8.2.3. Total Diagnosed Incident Population of CRBSI in Brazil
8.2.4. Diagnosed Incidence of CRBSI by Causative Pathogens in Brazil
8.3. Mexico Epidemiology
8.3.1. Assumptions and Rationale
8.3.2. Total Incident Population of CRBSI in Mexico
8.3.3. Total Diagnosed Incident Population of CRBSI in Mexico
8.3.4. Diagnosed Incidence of CRBSI by Causative Pathogens in Mexico
8.4. Colombia Epidemiology
8.4.1. Assumptions and Rationale
8.4.2. Total Incident Population of CRBSI in Colombia
8.4.3. Total Diagnosed Incident Population of CRBSI in Colombia
8.4.4. Diagnosed Incidence of CRBSI by Causative Pathogens in Colombia
9. Middle East Epidemiology
9.1. Saudi Arabia Epidemiology
9.1.1. Assumptions and Rationale
9.1.2. Total Incident Population of CRBSI in Saudi Arabia
9.1.3. Total Diagnosed Incident Population of CRBSI in Saudi Arabia
9.1.4. Diagnosed Incidence of CRBSI by Causative Pathogens in Saudi Arabia
9.2. United Arab Emirates Epidemiology
9.2.1. Assumptions and Rationale
9.2.2. Total Incident Population of CRBSI in the United Arab Emirates
9.2.3. Total Diagnosed Incident Population of CRBSI in the United Arab Emirates
9.2.4. Diagnosed Incidence of CRBSI by Causative Pathogens in the United Arab Emirates
10. Russia Epidemiology
10.1.1. Assumptions and Rationale
10.1.2. Total Incident Population of CRBSI in Russia
10.1.3. Total Diagnosed Incident Population of CRBSI in Russia
10.1.4. Diagnosed Incidence of CRBSI by Causative Pathogens in Russia
11. Appendix
11.1. Report Methodology
12. DelveInsight Capabilities
13. Disclaimer
14. About DelveInsight
List of Figures, Tables and Charts Available in Catheter-Related Bloodstream Infection (CRBSI) - Epidemiology Forecast to 2028
Table 1 Terminology: CLABSI or CRBSITable 2 Various Risk Factors of CRBSIs
Table 3 Total Incident Population of CRBSI in the Global Market (2017–2028 )
Table 4 Total Diagnosed Incident Population of CRBSI in the Global Market (2017–2028 )
Table 5 Total Incident Population of CRBSI in the US (2017–2028)
Table 6 Total Diagnosed Incident Population of CRBSI in the US (2017–2028)
Table 7 Diagnosed Incidence of CRBSI by Causative Pathogens in the US (2017–2028)
Table 8 Total Incident Population of CRBSI in Germany (2017–2028 )
Table 9 Total Diagnosed Incident Population of CRBSI in Germany (2017–2028)
Table 10 Diagnosed Incidence of CRBSI by Causative Pathogens in Germany (2017–2028)
Table 11 Total Incident Population of CRBSI in France (2017–2028)
Table 12 Total Diagnosed Incident Population of CRBSI in France (2017–2028)
Table 13 Diagnosed Incidence of CRBSI by Causative Pathogens in France (2017–2028)
Table 14 Total Incident Population of CRBSI in Italy (2017–2028)
Table 15 Total Diagnosed Incident Population of CRBSI in Italy (2017–2028)
Table 16 Diagnosed Incidence of CRBSI by Causative Pathogens in Italy (2017–2028 )
Table 17 Total Incident Population of CRBSI in Spain (2017–2028)
Table 18 Total Diagnosed Incident Population of CRBSI in Spain (2017–2028)
Table 19 Diagnosed Incidence of CRBSI by Causative Pathogens in Spain (2017–2028)
Table 20 Total Incident Population of CRBSI in the UK (2017–2028)
Table 21 Total Diagnosed Incident Population of CRBSI in the UK (2017–2028 )
Table 22 Diagnosed Incidence of CRBSI by Causative Pathogens in the UK (2017–2028)
Table 23 Total Incident Population of CRBSI in Japan (2017–2028)
Table 24 Total Diagnosed Incident Population of CRBSI in Japan (2017–2028)
Table 25 Diagnosed Incidence of CRBSI by Causative Pathogens in Japan (2017–2028)
Table 26 Total Incident Population of CRBSI in China (2017–2028)
Table 27 Total Diagnosed Incident Population of CRBSI in China (2017–2028)
Table 28 Diagnosed Incidence of CRBSI by Causative Pathogens in China (2017–2028)
Table 29 Total Incident Population of CRBSI in India (2017–2028)
Table 30 Total Diagnosed Incident Population of CRBSI in India (2017–2028 )
Table 31 Diagnosed Incidence of CRBSI by Causative Pathogens in India (2017–2028)
Table 32 Total Incident Population of CRBSI in Taiwan (2017–2028)
Table 33 Total Diagnosed Incident Population of CRBSI in Taiwan (2017–2028)
Table 34 Diagnosed Incidence of CRBSI by Causative Pathogens in Taiwan (2017–2028)
Table 35 Total Incident Population of CRBSI in South Korea (2017–2028)
Table 36 Total Diagnosed Incident Population of CRBSI in South Korea (2017–2028)
Table 37 Diagnosed Incidence of CRBSI by Causative Pathogens in South Korea (2017–2028)
Table 38 Total Incident Population of CRBSI in Australia (2017–2028)
Table 39 Total Diagnosed Incident Population of CRBSI in Australia (2017–2028)
Table 40 Diagnosed Incidence of CRBSI by Causative Pathogens in Australia (2017–2028)
Table 41 Total Incident Population of CRBSI in Argentina (2017–2028)
Table 42 Total Diagnosed Incident Population of CRBSI in Argentina (2017–2028)
Table 43 Diagnosed Incidence of CRBSI by Causative Pathogens in Argentina (2017–2028)
Table 44 Total Incident Population of CRBSI in Brazil (2017–2028)
Table 45 Total Diagnosed Incident Population of CRBSI in Brazil (2017–2028)
Table 46 Diagnosed Incidence of CRBSI by Causative Pathogens in Brazil (2017–2028)
Table 47 Total Incident Population of CRBSI in Mexico (2017–2028)
Table 48 Total Diagnosed Incident Population of CRBSI in Mexico (2017–2028)
Table 49 Diagnosed Incidence of CRBSI by Causative Pathogens in Mexico (2017–2028)
Table 50 Total Incident Population of CRBSI in Colombia (2017–2028)
Table 51 Total Diagnosed Incident Population of CRBSI in Colombia (2017–2028)
Table 52 Diagnosed Incidence of CRBSI by Causative Pathogens in Colombia (2017–2028)
Table 53 Total Incident Population of CRBSI in Saudi Arabia (2017–2028)
Table 54 Total Diagnosed Incident Population of CRBSI in Saudi Arabia (2017–2028)
Table 55 Diagnosed Incidence of CRBSI by Causative Pathogens in Saudi Arabia (2017–2028)
Table 56 Total Incident Population of CRBSI in the United Arab Emirates (2017–2028)
Table 57 Total Diagnosed Incident Population of CRBSI in the United Arab Emirates (2017–2028)
Table 58 Diagnosed Incidence of CRBSI by Causative Pathogens in the United Arab Emirates (2017–2028)
Table 59 Total Incident Population of CRBSI in Russia (2017–2028)
Table 60 Total Diagnosed Incident Population of CRBSI in Russia (2017–2028)
Table 61 Diagnosed Incidence of CRBSI by Causative Pathogens in Russia (2017–2028)
Figure 1 Types of Central Venous and Arterial Catheter and their sites of insertion
Figure 2 Important pathogenic determinants of catheter-related Infection
Figure 3 Potential sources of infection of a percutaneous intravascular device
Figure 4 Total Incident Population of CRBSI in the Global Market (2017–2028 )
Figure 5 Total Diagnosed Incident Population of CRBSI in the Global Market (2017–2028 )
Figure 6 Total Incident Population of CRBSI in the US (2017–2028)
Figure 7 Total Diagnosed Incident Population of CRBSI in the US (2017–2028)
Figure 8 Diagnosed Incidence of CRBSI by Causative Pathogens in the US (2017–2028)
Figure 9 Total Incident Population of CRBSI in Germany (2017–2028)
Figure 10 Total Diagnosed Incident Population of CRBSI in Germany (2017–2028)
Figure 11 Diagnosed Incidence of CRBSI by Causative Pathogens in Germany (2017–2028)
Figure 12 Total Incident Population of CRBSI in France (2017–2028)
Figure 13 Total Diagnosed Incident Population of CRBSI in France (2017–2028)
Figure 14 Diagnosed Incidence of CRBSI by Causative Pathogens in France (2017–2028)
Figure 15 Total Incident Population of CRBSI in Italy (2017–2028)
Figure 16 Total Diagnosed Incident Population of CRBSI in Italy (2017–2028)
Figure 17 Diagnosed Incidence of CRBSI by Causative Pathogens in Italy (2017–2028)
Figure 18 Total Incident Population of CRBSI in Spain (2017–2028)
Figure 19 Total Diagnosed Incident Population of CRBSI in Spain (2017–2028)
Figure 20 Diagnosed Incidence of CRBSI by Causative Pathogens in Spain (2017–2028)
Figure 21 Total Incident Population of CRBSI in the United Kingdom (2017–2028)
Figure 22 Total Diagnosed Incident Population of CRBSI in the United Kingdom (2017–2028 )
Figure 23 Diagnosed Incidence of CRBSI by Causative Pathogens in the United Kingdom (2017–2028)
Figure 24 Total Incident Population of CRBSI in Japan (2017–2028)
Figure 25 Total Diagnosed Incident Population of CRBSI in Japan (2017–2028)
Figure 26 Diagnosed Incidence of CRBSI by Causative Pathogens in Japan (2017–2028)
Figure 27 Total Incident Population of CRBSI in China (2017–2028)
Figure 28 Total Diagnosed Incident Population of CRBSI in China (2017–2028)
Figure 29 Diagnosed Incidence of CRBSI by Causative Pathogens in China (2017–2028)
Figure 30 Total Incident Population of CRBSI in India (2017–2028)
Figure 31 Total Diagnosed Incident Population of CRBSI in India (2017–2028 )
Figure 32 Diagnosed Incidence of CRBSI by Causative Pathogens in India (2017–2028 )
Figure 33 Total Incident Population of CRBSI in Taiwan (2017–2028)
Figure 34 Total Diagnosed Incident Population of CRBSI in Taiwan (2017–2028)
Figure 35 Diagnosed Incidence of CRBSI by Causative Pathogens in Taiwan (2017–2028)
Figure 36 Total Incident Population of CRBSI in South Korea (2017–2028)
Figure 37 Total Diagnosed Incident Population of CRBSI in South Korea (2017–2028)
Figure 38 Diagnosed Incidence of CRBSI by Causative Pathogens in South Korea (2017–2028)
Figure 39 Total Incident Population of CRBSI in Australia (2017–2028)
Figure 40 Total Diagnosed Incident Population of CRBSI in Australia (2017–2028)
Figure 41 Diagnosed Incidence of CRBSI by Causative Pathogens in Australia (2017–2028)
Figure 42 Total Incident Population of CRBSI in Argentina (2017–2028)
Figure 43 Total Diagnosed Incident Population of CRBSI in Argentina (2017–2028)
Figure 44 Diagnosed Incidence of CRBSI by Causative Pathogens in Argentina (2017–2028)
Figure 45 Total Incident Population of CRBSI in Brazil (2017–2028)
Figure 46 Total Diagnosed Incident Population of CRBSI in Brazil (2017–2028)
Figure 47 Diagnosed Incidence of CRBSI by Causative Pathogens in Brazil (2017–2028)
Figure 48 Total Incident Population of CRBSI in Mexico (2017–2028)
Figure 49 Total Diagnosed Incident Population of CRBSI in Mexico (2017–2028)
Figure 50 Diagnosed Incidence of CRBSI by Causative Pathogens in Mexico (2017–2028)
Figure 51 Total Incident Population of CRBSI in Colombia (2017–2028)
Figure 52 Total Diagnosed Incident Population of CRBSI in Colombia (2017–2028)
Figure 53 Diagnosed Incidence of CRBSI by Causative Pathogens in Colombia (2017–2028)
Figure 54 Total Incident Population of CRBSI in Saudi Arabia (2017–2028)
Figure 55 Total Diagnosed Incident Population of CRBSI in Saudi Arabia (2017–2028)
Figure 56 Diagnosed Incidence of CRBSI by Causative Pathogens in Saudi Arabia (2017–2028)
Figure 57 Total Incident Population of CRBSI in the United Arab Emirates (2017–2028)
Figure 58 Total Diagnosed Incident Population of CRBSI in the United Arab Emirates (2017–2028)
Figure 59 Diagnosed Incidence of CRBSI by Causative Pathogens in the United Arab Emirates (2017–2028)
Figure 60 Total Incident Population of CRBSI in Russia (2017–2028)
Figure 61 Total Diagnosed Incident Population of CRBSI in Russia (2017–2028 )
Figure 62 Diagnosed Incidence of CRBSI by Causative Pathogens in Russia (2017–2028)
